Loading...
XTSX
ADK
Market cap18mUSD
Jul 09, Last price  
0.27CAD
1D
1.92%
1Q
3.92%
Jan 2017
-79.62%
IPO
-99.66%
Name

Diagnos Inc

Chart & Performance

D1W1MN
XTSX:ADK chart
P/E
—
P/S
412.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.32%
Rev. gr., 5y
-27.70%
Revenues
65k
-36.92%
775,7201,863,1761,885,956358,0731,074,5131,327,8201,508,9072,704,974564,175981,4802,390,0511,612,821326,469326,469331,517267,073438,833170,158103,79765,477
Net income
-5m
L+6.27%
-617,133-398,085-2,079,903-1,910,838-1,074,271-2,192,979-2,043,717-1,640,784-2,827,588-3,192,431-5,420,641-2,897,165-3,839,056-3,839,056-3,382,873-2,051,303-2,608,218-3,120,582-4,286,449-4,555,199
CFO
-4m
L+9.88%
-876,299-547-1,747,464-1,506,911-1,408,841-1,906,675-2,008,399-1,213,753-2,866,405-2,233,132-1,786,903-2,243,595-2,319,721-2,319,721-2,640,705-1,356,799-2,037,943-2,147,432-3,637,452-3,996,692

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations focuses on healthcare, where it provides Computer Assisted Retina Analysis (CARA). This advanced web-based platform is designed to support medical professionals in the early detection of diabetic retinopathy. It also empowers eye care specialists by enabling clear visualization of both standard retinal features and any pathological changes. Beyond its healthcare offerings, DIAGNOS Inc. extends its expertise through consulting services, specializing in the fields of data analytics and artificial intelligence (AI). Established in 1998, the company maintains its corporate headquarters in Brossard, Canada.
URL
https://www.diagnos.com/
IPO date
Sep 27, 2000
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT